SEC Form 424B3 filed by Kazia Therapeutics Limited
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
Live Feed
Delayed 3mAnalyst · Insider · SEC · Financials
Signed out · 3-min delay · Sign up for real-time
- SEC Form 25-NSE filed by Bleichroeder Acquisition Corp. II
25-NSE - Bleichroeder Acquisition Corp. II (0002088295) (Subject)
- Director Kornfeld Steven closing all direct ownership in the company (SEC Form 4) to cover withholding tax
4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SEC Form 6-K filed by Kazia Therapeutics Limited
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SEC Form N-PX filed by Virtus Convertible & Income Fund
N-PX - Virtus Convertible & Income Fund (0001214935) (Filer)
- SEC Form SCHEDULE 13G filed by NFT Limited
SCHEDULE 13G - NFT Ltd (0001958713) (Subject)
- SEC Form 4 filed by Director Brun Scott C. to cover withholding tax
4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SEC Form N-CSRS filed by Cornerstone Total Return Fund Inc.
N-CSRS - CORNERSTONE TOTAL RETURN FUND INC (0000033934) (Filer)
- Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $4,914,190 worth of shares (9,500 units at $517.28) as part of a pre-agreed trading plan (SEC Form 4)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
- SEC Form FWP filed by Bank Nova Scotia Halifax Pfd 3
FWP - BANK OF NOVA SCOTIA (0000009631) (Subject)
- SEC Form 8-K filed by Red River Bancshares Inc.
8-K - RED RIVER BANCSHARES INC (0001071236) (Filer)
- Isabella Bank Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - ISABELLA BANK CORP (0000842517) (Filer)
- Capital Southwest Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - CAPITAL SOUTHWEST CORP (0000017313) (Filer)
- Director Gryska David W closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- Affirm reports fourth fiscal quarter 2026 results
Affirm Holdings, Inc. (NASDAQ:AFRM) ("Affirm") today reported financial results for its fiscal 2026 fourth quarter ended June 30, 2026. The results, which include a shareholder letter furnished to the U.S. Securities and Exchange Commission on Form 8-K, can be found in the "Quarterly Results" section of Affirm’s investor relations website at https://investors.affirm.com/. Affirm will host a conference call and webcast to discuss its financial results today at 2:00pm PT. Hosting the call will be Max Levchin, Founder and Chief Executive Officer, Michael Linford, President, and Rob O’Hare, Chief Financial Officer. The conference call will be webcast live from Affirm’s investor relations webs
- Director Wallace Peter C sold $648,210 worth of shares (1,904 units at $340.45), decreasing direct ownership by 8% to 22,859 units (SEC Form 4)
4 - APPLIED INDUSTRIAL TECHNOLOGIES INC (0000109563) (Issuer)
- SEC Form 4 filed by Director Vincent Richard G to satisfy withholding tax
4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SEC Form 6-K filed by IM Cannabis Corp.
6-K - IM Cannabis Corp. (0001792030) (Filer)